Anti-CD38 daratumumab (approved in 2015), anti-SLAMF7 elotuzumab (2015), and anti-CD38 isatuximab (2020) are mAbs used for the treatment of MM (25, 27, 28). Here, CD38 is linked to Miyoshi myopathy.